Endpoints News 生物医药· Shelby Livingston·· 1 天前AI 评分43
诺和诺德消费者端推进加码,Wegovy口服片与CagriSema蓄势待发
Novo’s consumer push gains momentum with Wegovy pill, CagriSema on deck
AI 导读
诺和诺德(Novo Nordisk)消费者端业务推进取得进展,Wegovy口服制剂及在研复方制剂CagriSema相继亮相。Ed Cinca结束四年离开后重返该公司担任CEO,推动产品线布局。上述两个品种均处于申报推进阶段,尚未进入上市应用环节。
正文
LAS VEGAS — When Ed Cinca returned to Novo after four years away, he barely recognized the place.
“I think the building’s the same, but that’s …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news